Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human Glypican 3 Antibodies:
anti-Mouse (Murine) Glypican 3 Antibodies:
anti-Rat (Rattus) Glypican 3 Antibodies:
Go to our pre-filtered search.
Human Monoclonal Glypican 3 Primary Antibody for ICC, IHC (fro) - ABIN335359
Couchman, Ljubimov, Sthanam, Horchar, Hassell: Antibody mapping and tissue localization of globular and cysteine-rich regions of perlecan domain III. in The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1995
Show all 7 Pubmed References
Human Polyclonal Glypican 3 Primary Antibody for IHC (p), WB - ABIN4369853
Lai, Sandhu, Yu, Han, Moser, Jackson, Guerrero, Aderca, Isomoto, Garrity-Park, Zou, Shire, Nagorney, Sanderson, Adjei, Lee, Thorgeirsson, Roberts: Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. in Hepatology (Baltimore, Md.) 2008
Show all 3 Pubmed References
Human Polyclonal Glypican 3 Primary Antibody for CyTOF, FACS - ABIN4899915
Sawada, Yoshikawa, Nobuoka, Shirakawa, Kuronuma, Motomura, Mizuno, Ishii, Nakachi, Konishi, Nakagohri, Takahashi, Gotohda, Takayama, Yamao, Uesaka, Furuse, Kinoshita, Nakatsura: Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. in Clinical cancer research : an official journal of the American Association for Cancer Research 2012
Show all 3 Pubmed References
Human Monoclonal Glypican 3 Primary Antibody for ICC, FACS - ABIN969523
Zittermann, Capurro, Shi, Filmus: Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. in International journal of cancer. Journal international du cancer 2010
Show all 2 Pubmed References
Cow (Bovine) Polyclonal Glypican 3 Primary Antibody for IHC, WB - ABIN2780199
Boily, Saikali, Sinnett: Methylation analysis of the glypican 3 gene in embryonal tumours. in British journal of cancer 2004
Show all 2 Pubmed References
Human Polyclonal Glypican 3 Primary Antibody for IHC, ELISA - ABIN1585811
Magistri, Leonard, Tang, Chan, Lee, Sicklick: The glypican 3 hepatocellular carcinoma marker regulates human hepatic stellate cells via Hedgehog signaling. in The Journal of surgical research 2014
Human Monoclonal Glypican 3 Primary Antibody for CyTOF, FACS - ABIN4899916
Haupt, Murali, Mun, Teplyuk, Mei, Stein, van Wijnen, Nurcombe, Cool: The heparan sulfate proteoglycan (HSPG) glypican-3 mediates commitment of MC3T3-E1 cells toward osteogenesis. in Journal of cellular physiology 2009
MOSPD1 is a possible candidate gene for DORV (show GDF1 Antibodies), probably in combination with GPC3. Further studies of the combined functions of MOSPD1 and GPC3 are needed, and identification of additional patients with MOSPD1 and GPC3 duplication should be pursued
Glypican-3 is correlated with the clinical malignant behavior of hepatocellular carcinoma and its phenotype changes from positive to negative during tumor cells differentia- tion.
The diagnostic sensitivity for hepatocellular carcinoma increased to 72.8% (206 of the 283) when glypican 3 was combined with alpha-fetoprotein (show AFP Antibodies).
The lncRNA glypican 3 antisense transcript 1 (GPC3-AS1 (show PTGDR Antibodies)) has been reported to be a potential biomarker for hepatocellular carcinoma (HCC (show FAM126A Antibodies)) screening. We observed a significant upregulation of GPC3-AS1 (show PTGDR Antibodies) in HCC (show FAM126A Antibodies). Increased expression of GPC3-AS1 (show PTGDR Antibodies) was associated with alpha-fetoprotein (show AFP Antibodies), tumor size, microvascular invasion, encapsulation, Barcelona Clinic Liver Cancer stage, and worse prognosis of HCC (show FAM126A Antibodies) patients.
study provides the first evidence that GPC3 can modulate the PCSK9 (show PCSK9 Antibodies) extracellular activity as a competitive binding partner to the LDLR (show LDLR Antibodies) in HepG2 cells.
By subsequent Sanger sequencing of genomic DNA we could map the chromosomal break points to define a deletion size of 43,617 bp including exons 5 and 6 of the GPC3 gene.
This is the first study in which the optimal HLA-A*0201 GPC3 epitopes were screened from a large number of candidates predicted by three software. The optimized HLA-A*0201 GPC3 peptides will provide new epitope candidates for hepatocellular carcinoma (HCC (show FAM126A Antibodies)) immunotherapy.
GPC3 and KRT19 (show KRT19 Antibodies) overexpression are associated with carcinogenesis, progression, and poor prognosis in patients with PDAC and a valuable biomarker for diagnosis of PDAC.
The clinical implication of GPC3 detection and targeting in the management of patients with hepatocellular carcinoma. Review.
Glypican 3 expression showed a significant difference between endometrioid endometrial carcinoma and serous endometrial carcinoma, and it was significantly correlated with tumor grade, stage and myometrial invasion
Data show that notum (show NOTUM Antibodies) and glypican-1 (show GPC1 Antibodies) and glypican-3 gene expression during colorectal cancer (CRC (show SCRIB Antibodies)) development and present evidence to suggest them as potential new biomarkers of CRC (show SCRIB Antibodies) pathogenesis.
Coupling of pGPC3 to liposomes was essential for effective priming of GPC3-specific CTLs.
The expression of GPC-3 was altered by DEN treatment.
Data suggest that GPC3 down-regulates hepatocyte proliferation by binding to hedgehog (show SHH Antibodies) (HH) and down-regulating the HH signaling pathway and binding with CD81 (show CD81 Antibodies), thus making it unavailable to bind to Hhex (show HHEX Antibodies) and causing its nuclear translocation.
Finding represents a rare four layer genomic overlap consisting of growth associated quantitative trait locus (QTL), body mass associated Gpc3 gene, highly conserved miRNA gene and mature miRNA seed SNP identified in the lean mouse.
Hepatocyte overexpression of GPC3 suppresses hepatocyte proliferation and liver regeneration and alters gene expression profiles.
glypican-3 is involved in the recruitment of M2-polarized tumor-associated macrophages in hepatocellular carcinoma
GPC3 inhibits the PI3K/Akt (show AKT1 Antibodies) anti-apoptotic pathway while it stimulates the p38MAPK (show MAPK14 Antibodies) stress-activated one in murine mammary adenocarcinoma LM3 cells
Gpc3 function in development of Simpson-Golabi-Behmel syndrome is IGF-independent
GPC3 knockout mice exhibit alterations in the Wnt (show WNT2 Antibodies) signaling pathway, which is also associated with the regulation of cell proliferation
Cell surface heparan sulfate proteoglycans are composed of a membrane-associated protein core substituted with a variable number of heparan sulfate chains. Members of the glypican-related integral membrane proteoglycan family (GRIPS) contain a core protein anchored to the cytoplasmic membrane via a glycosyl phosphatidylinositol linkage. These proteins may play a role in the control of cell division and growth regulation. The protein encoded by this gene can bind to and inhibit the dipeptidyl peptidase activity of CD26, and it can induce apoptosis in certain cell types. Deletion mutations in this gene are associated with Simpson-Golabi-Behmel syndrome, also known as Simpson dysmorphia syndrome. Alternative splicing results in multiple transcript variants.
, glypican proteoglycan 3
, heparan sulphate proteoglycan
, intestinal protein OCI-5
, secreted glypican-3
, defective in Simpson-Golabi-Behmel overgrowth syndrome
, proteoglycan GPC3
, Intestinal protein OCI-5